After trying nearly everything in its power to protect lead product Copaxone from early generic competition, Teva just received some news it least wants to hear: Copycats are going after its new, long-acting version of the drug, too.
Lawsuits against the FDA don't normally get much traction. Luckily for Hospira ($HSP), it has one that did. A federal judge has suspended the agency's decision allowing drugmakers to market certain generic copies of Hospira's top product--but it won't recall the copies that are already out there.
New generic competition in the U.S. always makes a sales organization uneasy because layoffs usually follow. But Hospira's branded sales team faces a double whammy.
The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.
Conspiring to keep distributors from working with generic drugmakers is a no-no in Brazil, and the country's antitrust regulator is fining Merck KGaA for allegedly doing just that. And while the move harkens back to a meeting that happened 5 years ago, it's reflective of actions taken more recently by regulators in the U.S. and EU.
Shedding noncore assets is the trend du jour in Big Pharma, and now another company may be jumping on the bandwagon. Belgium's UCB is reportedly looking into a sale of Kremers Urban Pharmaceuticals, its Princeton, NJ-based generics unit.
Mylan has been hunting for a buy. Now, it's found one. The Pittsburgh-based generics specialist is buying a big chunk of Abbott Laboratories' drug business, in a stock swap worth $5.3 billion. With $2 billion in annual sales, the products would jack up Mylan's top line by almost 30%.
The heart drug digoxin--a generic version of GlaxoSmithKline's Lanoxin--used to cost just pennies a pill, making it a prescription that insurance companies were more than happy to cover. Not anymore. The three companies that make generic digoxin have been increasing their prices, causing the cost of the drug to nearly double in the last year.
Indian generics makers have turned to a Washington, DC, consulting firm run by Ron Somers to counter its tarnished image as bad press from plant bans has put its standards into question.
FDA actions against India's Ranbaxy Laboratories ostensibly are keeping U.S. consumers safer, but much poorer. The plant bans have also shined a spotlight on how complex drug laws in the U.S. can work against consumers' best interests.